Evidence map›Paper›PMID 41131594›Full record

ReviewOne health outlook2025

Assessing rapid response mobile laboratory (RRML) capacities in Europe and Africa to improve One Health disease surveillance activities and pandemic preparedness across two continents.

Anette Trojnacki, Julien A Nguinkal, Jürgen May, Karin Rainer, Georg Gerhard Duscher, Lisa Winkelmayer, Ana Ungureanu, Eva Jaho, Angeliki Vlachostergiou, George Suciu and 17 more

Abstract readReview
In one paragraph

Review in One health outlook, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Anette TrojnackiBernhard-Nocht-Institute for Tropical Medicine (BNITM), Hamburg, Germany.
Julien A NguinkalBernhard-Nocht-Institute for Tropical Medicine (BNITM), Hamburg, Germany.
Jürgen MayBernhard-Nocht-Institute for Tropical Medicine (BNITM), Hamburg, Germany.
Karin RainerÖsterreichische Agentur für Gesundheit und Ernährungssicherheit (AGES), Vienna, Austria.
Georg Gerhard DuscherÖsterreichische Agentur für Gesundheit und Ernährungssicherheit (AGES), Vienna, Austria.
Lisa WinkelmayerÖsterreichische Agentur für Gesundheit und Ernährungssicherheit (AGES), Vienna, Austria.
Ana Ungureanu, Red Cross District 5, Bucharest, Romania.
Eva JahoEXUS AI Labs, Athens, Greece.
Angeliki VlachostergiouEXUS AI Labs, Athens, Greece.
George SuciuBEIA Consult International, Bucharest, Romania.
Cosmina StalidiBEIA Consult International, Bucharest, Romania.
Luminita MarcuBEIA Consult International, Bucharest, Romania.
Holger AnnusMDSC Systems OÜ, Tallinn, Estonia.
Kristjan KamdronMDSC Systems OÜ, Tallinn, Estonia.
Andry AasamäeMDSC Systems OÜ, Tallinn, Estonia.
Martin GroschupFriedrich-Loeffler-Institut (FLI), Federal Research Institute for Animal Health, Greifswald - Insel Riems, Germany.
Klaas DietzeFriedrich-Loeffler-Institut (FLI), Federal Research Institute for Animal Health, Greifswald - Insel Riems, Germany.
Sascha KnaufFriedrich-Loeffler-Institut (FLI), Federal Research Institute for Animal Health, Greifswald - Insel Riems, Germany.
Markus KellerFriedrich-Loeffler-Institut (FLI), Federal Research Institute for Animal Health, Greifswald - Insel Riems, Germany.
Kassiani MellouEthnikos Organismos Dimosias Ygeias, National Public Health Organization (NPHO), Athens, Greece.
Lida PolitiEthnikos Organismos Dimosias Ygeias, National Public Health Organization (NPHO), Athens, Greece.
Georg NeubauerAustrian Institute of Technology (AIT), Vienna, Austria.
Dražen IgnjatovićAustrian Institute of Technology (AIT), Vienna, Austria.
Aryse Martins MeloBernhard-Nocht-Institute for Tropical Medicine (BNITM), Hamburg, Germany.
Johannes R PehamAustrian Institute of Technology (AIT), Vienna, Austria.
Muna Affara *Bernhard-Nocht-Institute for Tropical Medicine (BNITM), Hamburg, Germany.
Florian Gehre *Bernhard-Nocht-Institute for Tropical Medicine (BNITM), Hamburg, Germany. gehre@bnitm.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEurope and Africa are increasingly affected by (re-)emerging risk group 3 and 4, zoonotic viral disease epidemics, which not only require diagnostic BSL-3/4 laboratory capacity but also a One Health-based control strategy for efficient outbreak containment. In many European and African countries such laboratory capacity is often not readily available, and rapid response mobile laboratories (RRMLs) can play important, complementary roles in outbreak responses and pandemic preparedness activities on national, regional and international level. MAIN BODY: The aim of the present review was to assess whether existing European and African RRML infrastructure is prepared for future One Health outbreak responses and to identify potential diagnostic gaps. Based on a literature review (2007-2021), we identified 291 mobile laboratories (Europe: 192, Africa: 99) and assessed them in respect to purpose (e.g. military, civilian), design (suitcase, modular, vehicle mounted), biosafety level, laboratory equipment, diagnostic portfolio, sample types analyzed (human, animal) and quality assurance measures. Following peaks in 2014 (Ebola/West Africa) and 2020 (COVID-19), mobile laboratory numbers have steadily increased. Whilst laboratories were originally designed to diagnose viral haemorrhagic fevers, there has been an increased focus on SARS-CoV-2 since 2020. Recently, there was a shift of African countries to develop an independent mobile laboratory capacity, rather than relying on external support for outbreak responses.

conclusionWe identified key shortcomings of existing laboratories, as the majority only process samples of human origin (not compliant with One Health principles), only 5% have sufficient capacity to diagnose emerging risk group 3/4 (arbo)viruses, 1-10% have accredited quality assurance systems in place, and mobile laboratories are not interconnected to allow concerted national and international responses. Our results reveal the gaps that should be addressed to make future responses to zoonotic, high-consequence pathogens more effective.

Indexed as

AfricaBSL-4Disease outbreaksEmerging diseasesEpidemicsEuropeMobile laboratoriesPandemic preparednessRisk group 3Risk group 4

Identifiers

PMID41131594
PMCPMC12548259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.